Journal for ImmunoTherapy of Cancer,
Journal Year:
2024,
Volume and Issue:
12(4), P. e008636 - e008636
Published: April 1, 2024
Immunotherapy
profoundly
changed
the
landscape
of
cancer
therapy
by
providing
long-lasting
responses
in
subsets
patients
and
is
now
standard
care
several
solid
tumor
types.
However,
immunotherapy
activity
beyond
conventional
immune
checkpoint
inhibition
plateauing,
biomarkers
are
overall
lacking
to
guide
treatment
selection.
Most
studies
have
focused
on
T
cell
engagement
response,
but
there
a
growing
evidence
that
B
cells
may
be
key
players
establishment
an
organized
notably
through
tertiary
lymphoid
structures.
Mechanisms
response
include
antibody-dependent
cellular
cytotoxicity
phagocytosis,
promotion
CD4+
CD8+
activation,
maintenance
antitumor
memory.
In
types,
higher
levels
cells,
specific
subpopulations,
or
presence
structures
been
associated
with
improved
outcomes
inhibitors.
The
fate
subpopulations
widely
influenced
cytokine
milieu,
versatile
roles
for
B-specific
cytokines
activating
factor
attracting
chemokine-1/CXCL13,
master
regulatory
role
IL-10.
Roles
cell-specific
checkpoints
such
as
TIM-1
emerging
could
represent
potential
therapeutic
targets.
Overall,
expanding
field
tumors
holds
promise
improvement
current
strategies
patient
MedComm,
Journal Year:
2024,
Volume and Issue:
5(1)
Published: Jan. 1, 2024
Abstract
Tertiary
lymphoid
structures
(TLS)
are
organized
aggregates
of
immune
cells
that
form
under
pathological
conditions.
However,
the
predictive
value
TLS
in
clear
cell
renal
carcinoma
(ccRCC)
for
immunotherapies
remains
unclear.
We
comprehensively
assessed
implications
prognosis
and
immunological
responses
spatial
maturation
heterogeneity
655
ccRCC
patients.
A
higher
proportion
early‐TLS
was
found
peritumoral
TLS,
while
intratumoral
mainly
comprised
secondary
follicle‐like
(SFL‐TLS),
indicating
markedly
better
survival.
Notably,
presence
especially
SFL‐TLS,
significantly
correlated
with
survival
objective
reflection
rate
patients
receiving
anti‐Programmed
Cell
Death
Protein‐1
(PD‐1)/Programmed
Death‐Ligand‐1
(PD‐L1)
immunotherapies.
In
cluster,
primary
tumor‐associated
macrophages,
Treg
infiltration
regions
increased
prominently,
suggesting
an
immunosuppressive
tumor
microenvironment.
Interestingly,
transcriptome
annotation
multispectral
fluorescence
showed
abundance
mature
plasma
within
has
capacity
to
produce
IgA
IgG,
which
demonstrate
response
rates
a
superior
subjected
immunotherapy.
conclusion,
this
study
revealed
on
status
clinical
responses,
allowing
improvement
precise
ccRCC.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Aug. 28, 2024
Tertiary
lymphoid
structures
(TLSs)
are
defined
as
aggregates
formed
in
non-hematopoietic
organs
under
pathological
conditions.
Similar
to
secondary
(SLOs),
the
formation
of
TLSs
relies
on
interaction
between
tissue
inducer
(LTi)
cells
and
organizer
(LTo)
cells,
involving
multiple
cytokines.
Heterogeneity
is
a
distinguishing
feature
TLSs,
which
may
lead
differences
their
functions.
Growing
evidence
suggests
that
associated
with
various
diseases,
such
cancers,
autoimmune
transplant
rejection,
chronic
inflammation,
infection,
even
ageing.
However,
detailed
mechanisms
behind
these
clinical
associations
not
yet
fully
understood.
The
by
TLS
maturation
localization
affect
immune
function
also
unclear.
Therefore,
it
necessary
enhance
understanding
development
at
cellular
molecular
level,
allow
us
utilize
them
improve
microenvironment.
In
this
review,
we
delve
into
composition,
mechanism,
potential
therapeutic
applications
TLSs.
Furthermore,
discuss
implications
role
markers
response
prognosis.
Finally,
summarize
methods
for
detecting
targeting
Overall,
provide
comprehensive
aim
develop
more
effective
strategies.
Cancer Research,
Journal Year:
2024,
Volume and Issue:
84(8), P. 1199 - 1209
Published: Feb. 21, 2024
Abstract
Tumor-associated
tertiary
lymphoid
structures
(TLS)
have
been
associated
with
favorable
clinical
outcomes
and
response
to
immune
checkpoint
inhibitors
in
many
cancer
types,
including
non–small
cell
lung
cancer.
Although
the
detailed
cellular
molecular
mechanisms
underlying
these
associations
not
fully
elucidated,
growing
preclinical
studies
are
helping
elucidate
at
basis
of
TLS
formation,
composition,
regulation
responses.
However,
a
major
challenge
remains
how
exploit
enhance
naïve
treatment-mediated
antitumor
Here,
we
discuss
current
understanding
tumor-associated
TLS,
models
that
can
be
used
study
them,
potential
therapeutic
interventions
boost
particular
focus
on
research.
American Society of Clinical Oncology Educational Book,
Journal Year:
2024,
Volume and Issue:
44(3)
Published: May 23, 2024
Traditionally
sarcomas
have
been
considered
immunologically
quiet
tumours,
with
low
tumour
mutational
burden
(TMB)
and
an
immunosuppressive
microenvironment
(TME),
consisting
of
decreased
T-cell
infiltration
elevated
levels
H1F1α,
macrophages
neutrophils.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Jan. 22, 2024
The
intricate
relationship
between
anti-tumor
immunity
and
autoimmunity
is
a
complex
yet
crucial
aspect
of
cancer
biology.
Tumor
microenvironment
often
exhibits
autoimmune
features,
phenomenon
that
involves
natural
the
induction
humoral
responses
against
self-antigens
during
tumorigenesis.
This
facilitated
by
orchestration
immunity,
particularly
within
organized
structures
like
tertiary
lymphoid
(TLS).
Paradoxically,
significant
number
patients
do
not
manifest
features
course
their
illness,
with
rare
instances
paraneoplastic
syndromes.
discrepancy
can
be
attributed
to
various
immune-mediated
locks,
including
regulatory
or
suppressive
immune
cells,
anergic
autoreactive
lymphocytes,
effector
cells
exhaustion
due
chronic
stimulation.
Overcoming
these
locks
holds
risk
induce
mechanisms
progression,
notably
observed
anti-immune
checkpoint
therapies,
in
contrast
more
conventional
treatments
chemotherapy
radiotherapy.
Therefore,
challenge
arises
managing
immune-related
adverse
events
(irAEs)
induced
inhibitors
treatment,
as
decoupling
them
from
activity
poses
clinical
dilemma.
review
summarizes
recent
advances
understanding
link
B-cell
driven
reactions
patients,
discusses
implications
this
relationship.
Cancer Discovery,
Journal Year:
2024,
Volume and Issue:
14(4), P. 625 - 629
Published: April 4, 2024
Summary:
The
transition
from
2D
to
3D
spatial
profiling
marks
a
revolutionary
era
in
cancer
research,
offering
unprecedented
potential
enhance
diagnosis
and
treatment.
This
commentary
outlines
the
experimental
computational
advancements
challenges
molecular
profiling,
underscoring
innovation
needed
imaging
tools,
software,
artificial
intelligence,
machine
learning
overcome
implementation
hurdles
harness
full
of
analysis
field.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 7, 2025
Gastric
cancer
is
a
common
malignant
tumor
of
the
digestive
tract,
and
its
treatment
remains
significant
challenge.
In
recent
years,
role
various
immune
cells
in
microenvironment
progression
has
gained
increasing
attention.
Immunotherapy,
primarily
based
on
checkpoint
inhibitors,
notably
improved
prognosis
patients
with
gastric
cancer;
however,
challenges
regarding
therapeutic
efficacy
persist.
Histological
features
within
microenvironment,
such
as
tertiary
lymphoid
structures
(TLSs),
tumor-infiltrating
lymphocytes,
proportion
intratumoral
stroma,
are
emerging
potentially
effective
prognostic
factors.
cancer,
TLSs
may
serve
local
hubs,
enhancing
ability
to
interact
recognize
antigens,
which
closely
linked
effectiveness
immunotherapy
survival
rates
patients.
However,
specific
cell
type
driving
TLS
formation
tumors
not
yet
been
elucidated.
Mature
B-cell
regions
containing
germinal
centers.
During
center
formation,
B
undergo
transformations
become
mature
function,
exerting
anti-tumor
effects.
Therefore,
targeting
could
provide
new
avenues
for
immunotherapy.
This
review,
combined
current
research
elaborates
relationship
between
aiming
guidance
precise
